covid
Buscar en
Allergologia et Immunopathologia
Toda la web
Inicio Allergologia et Immunopathologia Hypersensitivity to paroxetine
Información de la revista
Vol. 34. Núm. 3.
Páginas 125-126 (mayo 2006)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 34. Núm. 3.
Páginas 125-126 (mayo 2006)
Acceso a texto completo
Hypersensitivity to paroxetine
Hipersensibilidad a paroxetina
Visitas
6398
María T Soto Meraa, Beatriz Veleiro Péreza, Rosario Olivera Fernándezb, José F Filgueira Iglesiasa
a Unidad de Alergia. Complexo Hospitalario de Pontevedra. Spain.
b Servicio de Farmacología. Complexo Hospitalario de Pontevedra. Spain.
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
The increasingly extensive use of selective serotonin reuptake inhibitors will probably increase the number of cases of cutaneous reactions due to these drugs. This report describes a case of generalized exanthema due to paroxetine. Positive results to patch tests indicated delayed hypersensitivity.
Keywords:
Cutaneous adverse reaction
Delayed hypersensitivity
Patch test
Paroxetine
SSRIs
El aumento generalizado del uso de antidepresivos inhibidores de la recaptación selectiva de serotonina (SSRIs) probablemente dará lugar a un incremento de casos de reacciones cutáneas causadas por esos medicamentos. Se presenta un paciente con un exantema generalizado debido a la paroxetina demostrado mediante prueba de parche, lo que indica que se trata de una reacción de hipersensibilidad retardada.
Texto completo

Selective serotonin reuptake inhibitors antidepressants (SSRIs) have been widely used in recent years, but cutaneous adverse reactions have not often been reported. We describe a patient who developed a cutaneous reaction by paroxetine. Our case is of particular interest because we could demonstrate delayed hypersensitivity by patch testing.

CASE REPORT

A fifty-nine year-old woman who suffered from a depressive disorder received paroxetine 20 mg/day and alprazolam 0,50 mg/day. Several weeks later she was referred to our Unit because she developed an episode of generalized mild pruritc maculopapular exanthema. There was no mucosa or palm and sole involvement. She improved in a few days after treatment with corticosteroids, without scaling or residual lesions. A depression was diagnosed years ago and she took different drugs, but she did not remember their names. After this episode she was treated with amytriptiline.

ALLERGY TEST

Several weeks after the exanthema, we performed patch tests with paroxetine 1 % and 3 % in pet, with a positive reaction (2 +) in both at D3 (fig. 1). Eight controls were negative. To study a possible cross reactivity, we performed patch tests with another SSRI: sertraline 3 % pet, citalopram 3 % pet, fluoxetine 3 % pet and fluvoxetine 3 % pet, with negative results. The patient rejected a challenge test with any of these substances because she had alternatives. The patch test with alprazolam 5 % pet was negative and she started taking this drug again without any problem.

Figure 1.--Patch test.

DISCUSSION

Although SSRIs are widely used, there are only a few cases of cutaneous adverse reactions reported. Toxicodermias of different severity due to several of these drugs have been described. The most common type is a maculopapular rash 1-4 like our patient, but vasculitis 3,5, necrolisis epidermal toxic 6,7, Stevens-Jonhson 7, photodermatitis 3,8 and pseudolinfoma 9 have been reported too. The onset of these reactions usually occurs a few days after the drug has been introduced 1-4 but in our case the first lesions did not appear until several weeks later. In one case the diagnosis was made with a patch test 3, but there is no reference to the concentration and vehicle.

Cross reactivity between SSRIs is described in spite of their different chemical structures 1,2,4. In our case we could not demonstrate this because the epicutaneous tests were negative and the patient rejected the challenge tests.

SUMMARY

The increasingly extensive use of SSRIs will probably result in a increase in cases of cutaneous reactions due to these drugs. This case describes a generalized exanthema by paroxetine and the positive result of the pacht test indicates delayed hipersensitivy.

Bibliography
[1]
Beauquier B, Fash H..
Effets secondaires dermatologiques des antidépresseurs inhibiteurs de la recapture de la sérotonine: hypothèse d'une allergie croisée. A propos de deux cas..
L'Encephale, 24 (1998), pp. 62-4
[2]
Tracie JS, Martha CF, Johan SM..
Selective serotonine reuptake inhibitor-induced rash: case report and review of the Literature..
Pharmacotherpy, 22 (2002), pp. 516-8
[3]
Richard MA, Fiszenson F, Jreissati M, Jean Pastor MJ, Grob JJ..
Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: 2 cases..
Ann Dermatol Venereol, 128 (2001), pp. 759-61
[4]
Caroline A Warnoc.k, Abbas G Azadian..
Cross-sensitiviy between paroxetine and sertraline..
Ann Pharmacotherapy, 36 (2002), pp. 631-3
[5]
Howard C..
Margolese, Guy Chouinard, Linda Beauclair, Michael Rubino. Cutaneous vasculitis induced by paroxetine (letter)..
Am J Psychiatry, 158 (2001), pp. 497
[6]
Wolkenstein P, Revuz J, Diehl JL, LAngeron O, Roupie E, Machet L..
Toxic epidemal necrolysis after fluvoxamine..
Lancet, 342 (1993), pp. 304-5
[7]
Bodokh I, Lacour JP, Rosenthal E, Chichmanian RM, Perrin C, Vietta A, et al..
Syndrome de Lyell ou nécrolyse épidermique toxique et syndrome de Stevens-Johnson après traitment par fluoxetine..
Therapie, 47 (1992), pp. 441
[8]
Gaufberg E, Ellison JM..
Photosensitivity reaction to fluoxetine..
J Clin Psychiatry, 56 (1995), pp. 486
[9]
Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Dommer P, Roegnigk H, Rosen S..
Pseudo-mycosis fungoides in a patient taking clonacepam and fluoxetine..
J Am Acad Dermatol, 34 (1996), pp. 304-6
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos